Another pertinent question to resolve, before short- or long-term therapy with MMP-9 inhibitors is clinically tested, relates to whether MMP-9 is contributing mainly to acute inflammation in IBD or that it also contributes to chronic inflammatory and fibrosis processes and pathological angiogenesis, as are observed in diabetic retinopathy (24). This evidence concerns the gene MMP9 and inflammatory bowel disease.